DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Non-glutamatergic clozapine augmentation strategies: a review and meta-analysis.

Author(s): Veerman SR(1), Schulte PF(2), Begemann MJ(3), de Haan L(4).

Affiliation(s): Author information: (1)Flexible Assertive Community Treatment, Mental Health Service Organisation North Holland North, Community Mental Health Division, Alkmaar, The Netherlands. (2)Treatment Centre for Bipolar Disorders, Mental Health Service Organisation North Holland North, Division for Specialised Treatment, Alkmaar, The Netherlands. (3)Neuroscience Department & Rudolf Magnus Institute for Neuroscience, University Medical Center Utrecht, UMCU, Utrecht, The Netherlands. (4)Early Psychosis Department, AMC, Academic Psychiatric Centre, Amsterdam, The Netherlands.

Publication date & source: 2014, Pharmacopsychiatry. , 47(7):231-8

Persistent negative symptoms and cognitive impairment are major clinical problems in the treatment of schizophrenia. There is no convincing evidence regarding the efficacy of augmentation of clozapine with a second antipsychotic, ethyl eicosapentaenoic acid (E-EPA), an antidepressant, a mood stabilizer or extract of Ginkgo biloba in clozapine-resistant schizophrenia. We present an overview of studies in which the potential clinical utility of the addition of non-glutamatergic agents to clozapine is assessed. We performed a meta-analysis on the efficacy of both risperidone and aripiprazole compared to placebo. We compared the effects of the addition of a second antipsychotic or an antidepressant to clozapine on positive, negative, overall and affective symptoms of schizophrenia in double-blind placebo-controlled trials.

Page last updated: 2015-08-10

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017